Two dead, one injured as rally car crashes into spectators in central France
Two spectators were killed and another seriously injured on Saturday when a rally car veered off the road during a race near Ambert in France’s Puy-...
A new long-acting preventive HIV drug, lenacapavir, could be available in the world’s poorest countries by late 2025 or early 2026, according to Hui Yang, head of supply operations at the Global Fund to Fight AIDS, Tuberculosis and Malaria.
According to Hui Yang of the Global Fund, lenacapavir, a new long-acting preventive HIV drug, may be available in the world’s poorest countries by late 2025 or early 2026.
The timeline depends on regulatory approvals from authorities like the U.S. Food and Drug Administration and the World Health Organization, Yang said.
Lenacapavir is already approved as a treatment for multi-drug resistant HIV in the U.S., where it costs around $42,250 for the first year of therapy. Recent clinical trials have also demonstrated its effectiveness in preventing HIV infection, prompting Gilead Sciences to seek global approval for this new use.
Yang stressed the need for low and middle-income countries to have timely access to the drug, stating, "We don't want...low and low-middle income countries to wait, to be at the back of the line." This issue has long been a barrier in the fight against HIV.
To ensure affordable access, the Global Fund is collaborating with the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), along with funding from the Children’s Investment Fund Foundation and the Bill & Melinda Gates Foundation. Together, they aim to provide lenacapavir to at least two million people in participating countries over three years.
In October, Gilead signed agreements with six generic drugmakers to produce lenacapavir more affordably for 120 low and middle-income countries. However, the deal faced criticism for excluding some regions, particularly in Latin America. Yang stated that while no agreements have been finalized with Gilead or the generic producers, they will work with all involved companies.
The world’s biggest dance music festival faces an unexpected setback as a fire destroys its main stage, prompting a last-minute response from organisers determined to keep the party alive in Boom, Belgium.
Australian researchers have created a groundbreaking “biological AI” platform that could revolutionise drug discovery by rapidly evolving molecules within mammalian cells.
Australian researchers have pioneered a low-cost and scalable plasma-based method to produce ammonia gas directly from air, offering a green alternative to the traditional fossil fuel-dependent Haber-Bosch process.
A series of earthquakes have struck Guatemala on Tuesday afternoon, leading authorities to advise residents to evacuate from buildings as a precaution against possible aftershocks.
The U.S. economy faces a 40% risk of recession in the second half of 2025, JP Morgan analysts said on Wednesday, citing rising tariffs and stagflation concerns.
Honduras has brought back mask mandates as COVID-19 cases and a new variant surge nationwide.
The World Health Organization (WHO) warned on Tuesday that the world could be on the brink of another chikungunya epidemic, similar to the 2005 outbreak, unless swift measures are implemented to control its spread.
Every Sunday evening at Chicago’s North Avenue Beach, the sound of collective shouting echoes across Lake Michigan – not from protestors, but from Scream Club Chicago, a group gathering to relieve stress by screaming into the open air.
A major study warns that antibiotic-resistant superbugs could kill millions each year while shrinking the global economy by almost $2 trillion annually by 2050, a crisis driven in part by international aid cuts that undermine resistance efforts.
The United States has rejected a global pandemic treaty adopted by the World Health Organization (WHO), saying it threatens national sovereignty and lacks clear language.
You can download the AnewZ application from Play Store and the App Store.
What is your opinion on this topic?
Leave the first comment